Genetic variation in the CYP2B6 Gene is related to circulating 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) concentrations: An observational population-based study

Environmental Health: A Global Access Science Source

Volumn 13, Issue 1, 2014, Pages

  Penell, Johanna ^a   Lind, Lars ^a   Fall, Tove ^a   Syvänen, Anne Christine ^a   Axelsson, Tomas ^a   Lundmark, Per ^a   Morris, Andrew P ^b   Lindgren, Cecilia ^b   Mahajan, Anubha ^b   Salihovic, Samira ^c   Van Bavel, Bert ^c   Ingelsson, Erik ^a,b   Lind, P Monica ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ÖREBRO UNIVERSITY   (Sweden)

Author keywords

2,2',4,4' tetrabromodiphenyl ether; BDE 47; CYP; Elderly; Epidemiology; Gene; SNP

Indexed keywords

2,2',4,4' TETRACHLOROBIPHENYL; CYTOCHROME P450 2B6;

BLOOD; COHORT ANALYSIS; CONCENTRATION (COMPOSITION); ELDERLY POPULATION; ENZYME ACTIVITY; EPIDEMIOLOGY; ETHER; GENE EXPRESSION; GENETIC VARIATION; POLLUTION EXPOSURE; PUBLIC HEALTH;

AGED; ARTICLE; CONCENTRATION (PARAMETERS); FEMALE; GAS CHROMATOGRAPHY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

SWEDEN; UPPSALA [SWEDEN];

AGED; ARYL HYDROCARBON HYDROXYLASES; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; FEMALE; HALOGENATED DIPHENYL ETHERS; HUMANS; LIPIDS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SWEDEN;

EID: 84901243332     PISSN: None     EISSN: 1476069X     Source Type: Journal    
DOI: 10.1186/1476-069X-13-34     Document Type: Article

References (55)

1. WHO, World Health Organization. Environmental health criteria 192: Flame retardants: a general introduction 1997
2. Environmental impact of flame retardants (persistence and biodegradability). Segev O, Kushmaro A, Brenner A, Int J Environ Res Public Health 2009 6 478 491 19440395
3. WHO, World Health Organization. Persistent organic pollutants impact on child health 2010
4. Brominated flame retardants: cause for concern? Birnbaum LS, Staskal DF, Environ Health Perspect 2004 112 9 17 10.1289/ehp.1121c9 14698924 (Pubitemid 38081507)
5. Associations between serum levels of polybrominated diphenyl ether (PBDE) flame retardants and environmental and behavioral factors in pregnant women. Buttke DE, Wolkin A, Stapleton HM, Miranda ML, J Expo Sci Environ Epidemiol 2013 23 176 182 10.1038/jes.2012.67 22760441
6. Prenatal exposure to PBDEs and neurodevelopment. Herbstman JB, Sjodin A, Kurzon M, Lederman SA, Jones RS, Rauh V, Needham LL, Tang D, Niedzwiecki M, Wang RY, Perera F, Environ Health Perspect 2010 118 5 712 719 10.1289/ehp.0901340 20056561
7. Associations between brominated flame retardants in house dust and hormone levels in men. Johnson PI, Stapleton HM, Mukherjee B, Hauser R, Meeker JD, Sci Total Environ 2013 445-446 177 184
8. Assessment of polybrominated diphenyl ethers (PBDEs) in serum from the Korean general population. Kim J, Kang JH, Park H, Baek SY, Kim YH, Chang YS, Environ Pollut 2012 164 46 52 22327115
9. Distribution of polybrominated diphenyl ethers (PBDEs) and other persistent organic pollutants in human serum from Greece. Kalantzi OI, Geens T, Covaci A, Siskos PA, Environ Int 2011 37 349 353 10.1016/j.envint.2010.10.005 21059472
10. Polybromodiphenyl ethers in mothers and their newborns from a non-occupationally exposed population (Valencia, Spain). Vizcaino E, Grimalt JO, Lopez-Espinosa MJ, Llop S, Rebagliato M, Ballester F, Environ Int 2011 37 152 157 10.1016/j.envint.2010.08.011 20864175
11. Dietary exposure to brominated flame retardants correlates with male blood levels in a selected group of Norwegians with a wide range of seafood consumption. Knutsen HK, Kvalem HE, Thomsen C, Froshaug M, Haugen M, Becher G, Alexander J, Meltzer HM, Mol Nutr Food Res 2008 52 217 227 10.1002/mnfr. 200700096 18246586
12. Serum concentrations of polybrominated diphenyl ethers (PBDEs) and polybrominated biphenyl (PBB) in the United States population: 2003-2004. Sjodin A, Wong LY, Jones RS, Park A, Zhang Y, Hodge C, Dipietro E, McClure C, Turner W, Needham LL, Patterson DG Jr, Environ Sci Technol 2008 42 4 1377 1384 10.1021/es702451p 18351120 (Pubitemid 351287207)
13. Polybrominated diphenyl ethers in the environment and in people: a meta-analysis of concentrations. Hites RA, Environ Sci Technol 2004 38 945 956 10.1021/es035082g 14998004 (Pubitemid 38228706)
14. Circulating levels of persistent organic pollutants (POPs) among elderly men and women from Sweden: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS). Salihovic S, Lampa E, Lindstrom G, Lind L, Lind PM, van Bavel B, Environ Int 2012 44 59 67 22361238
15. Advances in Molecular Modeling of Human Cytochrome P450 Polymorphism. Martiny VY, Miteva MA, J Mol Biol 2013 425 3978 3992 10.1016/j.jmb.2013.07.010 23856621
16. Toxicokinetics of polybrominated diphenyl ether congeners 47, 99, 100, and 153 in mice. Staskal DF, Hakk H, Bauer D, Diliberto JJ, Birnbaum LS, Toxicol Sci 2006 94 28 37 10.1093/toxsci/kfl091 16936226 (Pubitemid 44542327)
17. CYP2B6 gene single nucleotide polymorphisms and leukemia susceptibility. Yuan ZH, Liu Q, Zhang Y, Liu HX, Zhao J, Zhu P, Ann Hematol 2011 90 293 299 10.1007/s00277-010-1085-z 20878158
18. Biotransformation of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) by human liver microsomes: identification of cytochrome P450 2B6 as the major enzyme involved. Erratico CA, Szeitz A, Bandiera SM, Chem Res Toxicol 2013 26 721 731 10.1021/tx300522u 23537005
19. Biotransformation of BDE-47 to potentially toxic metabolites is predominantly mediated by human CYP2B6. Feo ML, Gross MS, McGarrigle BP, Eljarrat E, Barcelo D, Aga DS, Olson JR, Environ Health Perspect 2013 121 440 446 23249762
20. A technical mixture of 2,2',4,4'-tetrabromo diphenyl ether (BDE47) and brominated furans triggers aryl hydrocarbon receptor (AhR) mediated gene expression and toxicity. Wahl M, Lahni B, Guenther R, Kuch B, Yang L, Straehle U, Strack S, Weiss C, Chemosphere 2008 73 209 215 10.1016/j.chemosphere.2008.05. 025 18619640
21. Cytochrome P450 variations in different ethnic populations. McGraw J, Waller D, Expert Opin Drug Metab Toxicol 2012 8 371 382 10.1517/17425255.2012. 657626 22288606
22. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM, Pharmacogenetics 2001 11 399 415 10.1097/00008571-200107000-00004 11470993 (Pubitemid 32656581)
23. Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Li J, Menard V, Benish RL, Jurevic RJ, Guillemette C, Stoneking M, Zimmerman PA, Mehlotra RK, Pharmacogenomics 2012 13 555 570 10.2217/pgs.11.160 22462748
24. Polymorphic Cytochrome P450 Enzymes (CYPs) and Their Role in Personalized Therapy. Preissner SC, Hoffmann MF, Preissner R, Dunkel M, Gewiess A, Preissner S, PLoS One 2013 8 82562 10.1371/journal.pone.0082562 24340040
25. Functional characterization of cytochrome P450 2B6 allelic variants. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, Ando M, Drug Metab Dispos 2003 31 398 403 10.1124/dmd.31.4.398 12642465 (Pubitemid 36378517)
26. CYP24A1 and CYP27B1 polymorphisms modulate vitamin D metabolism in colon cancer cells. Jacobs ET, Van Pelt C, Forster RE, Zaidi W, Hibler EA, Galligan MA, Haussler MR, Jurutka PW, Cancer Res 2013 73 2563 2573 10.1158/0008-5472.CAN- 12-4134 23423976
27. Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population. Davaalkham J, Hayashida T, Tsuchiya K, Gatanaga H, Nyamkhuu D, Oka S, Drug Metab Dispos 2009 37 1991 1993 10.1124/dmd.109.027755 19581387
28. CYP2B6 polymorphisms influence the plasma concentration and clearance of the methadone S-enantiomer. Wang SC, Ho IK, Tsou HH, Tian JN, Hsiao CF, Chen CH, Tan HK, Lin L, Wu CS, Su LW, Huang CL, Yang YH, Liu ML, Lin KM, Chen CY, Liu SC, Wu HY, Chan HW, Tsai MH, Lin PS, Liu YL, J Clin Psychopharmacol 2011 31 4 463 469 10.1097/JCP.0b013e318222b5dd 21694616
29. Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study. Dobrinas M, Crettol S, Oneda B, Lahyani R, Rotger M, Choong E, Lubomirov R, Csajka C, Eap CB, Pharmacogenet Genomics 2013 23 84 93 10.1097/FPC.0b013e32835cb2e2 23249875
30. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort. Carr DF, la Porte CJ, Pirmohamed M, Owen A, Cortes CP, J Antimicrob Chemother 2010 65 1889 1893 10.1093/jac/dkq260 20639527
31. A comparison of three different methods to evaluate endothelium-dependent vasodilation in the elderly: the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Lind L, Fors N, Hall J, Marttala K, Stenborg A, Arterioscler Thromb Vasc Biol 2005 25 2368 2375 10.1161/01.ATV.0000184769. 22061.da 16141402 (Pubitemid 41552656)
32. Comprehensive solid-phase extraction method for persistent organic pollutants. Validation and application to the analysis of persistent chlorinated pesticides. Sandau CD, Sjodin A, Davis MD, Barr JR, Maggio VL, Waterman AL, Preston KE, Preau JL Jr, Barr DB, Needham LL, Patterson DG Jr, Anal Chem 2003 75 1 71 77 10.1021/ac026121u 12530820 (Pubitemid 36083470)
33. A rapid method for screening of the Stockholm Convention POPs in small amounts of human plasma using SPE and HRGC/HRMS. Salihovic S, Mattioli L, Lindstrom G, Lind L, Lind PM, van Bavel B, Chemosphere 2012 86 747 753 10.1016/j.chemosphere.2011.11.006 22153485
34. Imputation of data values that are less than a detection limit. Succop PA, Clark S, Chen M, Galke W, J Occup Environ Hyg 2004 1 436 441 10.1080/15459620490462797 15238313 (Pubitemid 38901819)
35. Estimating mean exposures from censored data: exposure to benzene in the Australian petroleum industry. Glass DC, Gray CN, Ann Occup Hyg 2001 45 275 282 10.1093/annhyg/45.4.275 11378148
36. Method of median semi-variance for the analysis of left-censored data: comparison with other techniques using environmental data. Zoffoli HJ, Varella CA, do Amaral-Sobrinho NM, Zonta E, Tolon-Becerra A, Chemosphere 2013 93 1701 1709 10.1016/j.chemosphere.2013.05.041 23830887
37. A simplified precise method for adjusting serum levels of persistent organohalogen pollutants to total serum lipids. Rylander L, Nilsson-Ehle P, Hagmar L, Chemosphere 2006 62 333 336 10.1016/j.chemosphere.2005.04.107 16005493 (Pubitemid 41744050)
38. Toxicokinetics of BDE 47 in female mice: effect of dose, route of exposure, and time. Staskal DF, Diliberto JJ, DeVito MJ, Birnbaum LS, Toxicol Sci 2005 83 215 223 15509665 (Pubitemid 40227891)
39. Flame Retardant BDE-47 Effectively Activates Nuclear Receptor CAR in Human Primary Hepatocytes. Sueyoshi T, Li L, Wang H, Moore R, Kodavanti PR, Lehmler HJ, Negishi M, Birnbaum LS, Toxicol Sci 2014 137 292 302 10.1093/toxsci/kft243 24218150
40. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro. Weiss J, Haefeli WE, Int J Antimicrob Agents 2013 41 484 487 10.1016/j.ijantimicag.2013.01.004 23428312
41. The evaluation of CYP2B6 inhibition by artemisinin antimalarials in recombinant enzymes and human liver microsomes. Ericsson T, Masimirembwa C, Abelo A, Ashton M, Drug Metab Lett 2012 6 247 257 23506555
42. Role of cytochrome P4502B6 in methadone metabolism and clearance. Kharasch ED, Stubbert K, J Clin Pharmacol 2013 53 305 313 10.1002/jcph.1 23361846
43. In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties. Dickmann LJ, VandenBrink BM, Lin YS, Drug Metab Dispos 2012 40 1263 1267 10.1124/dmd.112.044909 22531045
44. Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M, Schwab M, Zanger UM, Pharmacogenet Genomics 2005 15 861 873 10.1097/01213011-200512000-00004 16272958 (Pubitemid 41666768)
45. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Sukasem C, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Chamnanphol M, Puangpetch A, Sungkanuparph S, Infection 2013 Nov 30:Epub ahead of print
46. Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism. Sukasem C, Manosuthi W, Koomdee N, Santon S, Jantararoungtong T, Prommas S, Chamnanphol M, Puangpetch A, Sungkanuparph S, Infection 2013 2013 Epub ahead of print
47. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Desta Z, Saussele T, Ward B, Blievernicht J, Li L, Klein K, Flockhart DA, Zanger UM, Pharmacogenomics 2007 8 547 558 10.2217/14622416.8.6.547 17559344 (Pubitemid 46947859)
48. CYP2B6 (c.516G→ T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients. Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH, Br J Clin Pharmacol 2009 67 427 436 10.1111/j.1365-2125.2009.03368.x 19371316
49. Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece. Mastrogianni O, Gbandi E, Orphanidis A, Raikos N, Goutziomitrou E, Kolibianakis EM, Tarlatzis BC, Goulas A, Drug Metab Pharmacokinet 2013 Epub ahead of print
50. CYP2B6*6 is associated with increased breast cancer risk. Justenhoven C, Pentimalli D, Rabstein S, Harth V, Lotz A, Pesch B, Bruning T, Dork T, Schurmann P, Bogdanova N, Park-Simon TW, Couch FJ, Olson JE, Fasching PA, Beckmann MW, Haberle L, Ekici A, Hall P, Czene K, Liu J, Li J, Baisch C, Hamann U, Ko YD, Brauch H, Int J Cancer 2014 134 2 426 430 10.1002/ijc.28356 23824676
51. CYP2B6 non-coding variation associated with smoking cessation is also associated with differences in allelic expression, splicing, and nicotine metabolism independent of common amino-acid changes. Bloom AJ, Martinez M, Chen LS, Bierut LJ, Murphy SE, Goate A, PLoS One 2013 8 79700 10.1371/journal.pone. 0079700 24260284
52. The impact of genetic factors on response to anaesthetics. Mikstacki A, Skrzypczak-Zielinska M, Tamowicz B, Zakerska-Banaszak O, Szalata M, Slomski R, Adv Med Sci 2013 58 9 14 23640947
53. CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Wang H, Tompkins LM, Curr Drug Metab 2008 9 598 610 10.2174/138920008785821710 18781911
54. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Ring HZ, Valdes AM, Nishita DM, Prasad S, Jacob P 3rd, Tyndale RF, Swan GE, Benowitz NL, Pharmacogenet Genomics 2007 17 1007 1015 10.1097/01.fpc.0000220560. 59972.33 18004205 (Pubitemid 351339485)
55. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Miksys S, Tyndale RF, Drug Metab Rev 2004 36 313 333 10.1081/DMR-120034149 15237857 (Pubitemid 38802491)